PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company
focused on developing new therapeutic drugs to treat acute
cardiovascular disorders and infectious diseases, has presented for the
first time to the medical community data from its Phase 1B clinical
study with its defensin-mimetic antibiotic compound, PMX-30063. The data
were presented today at the 8th World Congress on Trauma,
Shock, Inflammation and Sepsis (TSIS) in Munich, Germany. TSIS is a
medical conference which focuses on the latest knowledge, developments
and innovative concepts related to the recognition of disease as well as
patient care and therapy within the wide field of acute and chronic
systemic inflammation.
“An
Approach to New Antibiotics for Avoiding Resistance: PMX-30063”
PolyMedix’s Vice President of Clinical Development and Chief Medical
Officer, Dr. Eric McAllister, presented during a session that focused on
the problem of bacterial drug resistance to antibiotics, superbugs and
the need for new antibiotic drugs. His presentation entitled, “An
Approach to New Antibiotics for Avoiding Resistance: PMX-30063”,
described the results to date from the Phase 1B dose-escalation clinical
study which showed that the administration of multiple doses of
PMX-30063 is safe and well-tolerated, with no clinically significant
adverse effects at potential therapeutic dose levels. Dr. McAllister
also presented data showing that PMX-30063 kills Staph bacteria,
including MRSA, in human serum in blood samples drawn from study
subjects at these same potential therapeutic dose levels.
PolyMedix’s novel antibiotic compound, PMX-30063, is a small molecule
mimetic of human host-defense proteins, one of the oldest and most
effective antimicrobial defense systems found in virtually all living
creatures. PMX-30063 has unique properties including a mechanism of
action that is completely different from current antibiotic drugs.
PMX-30063 directly disrupts the bacterial cell membrane, which is
intended to make bacterial resistance unlikely to develop. In addition,
it is fast acting and kills bacteria directly (bactericidal) rather than
simply stopping bacterial reproduction (bacteriostatic, like many other
antibiotic drugs). PMX-30063 is believed to be the first antibiotic with
this mechanism of action being developed for use in systemic infections.
U.S. restaurants face scrutiny over antibiotic policies